Matthew A. Lunning, DO

A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.

A panel of experts discuss how to sequence BTK inhibitors and CAR T-cell therapies in patients with MCL.

Experts on mantle cell lymphoma discuss third-line treatment options available for patients.

Experts on mantle cell lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline MCL.

Experts on mantle cell lymphoma discuss first-line treatment options available for patients.

Laurie Sehn, MD, and Bijal Shah, MD, discuss remaining unmet needs for patients with relapsed/refractory FL.

Peter Martin, MD, discusses how to sequence bispecific T-cell engagers and CAR T-cell therapies in the third-line and beyond setting for FL.

Jennifer Crombie, MD, discusses how to choose CAR T-cells as third-line and beyond therapy for FL.

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Matthew Lunning, DO, discusses the efficacy of axicabtagene ciloleucel in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Matthew A. Lunning, DO, discusses initial treatment considerations in chronic lymphocytic leukemia.

Matthew A. Lunning, DO, assistant professor, Internal Medicine Division of Oncology & Hematology, University of Nebraska Medical Center, discusses the treatment of patients with peripheral T-cell lymphoma.